BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 30, 2024.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.

ImmunityBio, Inc., has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin.

4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, announced the formation of its Clinical Advisory Board comprised of five physician scientists and leaders in the treatment and research of a variety of neuropsychiatric and neurodegenerative conditions.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024.

According to Vision Research Reports, the U.S. biotechnology market size was valued at USD 552.43 billion in 2023 and is anticipated to hit around USD 1,785.96 billion by 2033, growing at a CAGR of 12.45% from 2024

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.